Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development
Psyence BioMed Ltd., a Nasdaq-listed biopharmaceutical company specializing in psychedelic therapeutics, welcomed the U.S. administration's recent announcement to accelerate the development of ibogaine as a medical treatment. The move includes access to historical IND applications and collaboration between HHS, VA, and FDA to expand research and ri…